JP2015510880A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015510880A5 JP2015510880A5 JP2014560859A JP2014560859A JP2015510880A5 JP 2015510880 A5 JP2015510880 A5 JP 2015510880A5 JP 2014560859 A JP2014560859 A JP 2014560859A JP 2014560859 A JP2014560859 A JP 2014560859A JP 2015510880 A5 JP2015510880 A5 JP 2015510880A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- group
- composition according
- region
- liver disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920000642 polymer Polymers 0.000 claims description 11
- 108060003951 Immunoglobulin Proteins 0.000 claims description 10
- 102000018358 immunoglobulin Human genes 0.000 claims description 10
- 125000001151 peptidyl group Chemical group 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 125000003172 aldehyde group Chemical group 0.000 claims description 4
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims description 4
- -1 succinimidyl carboxymethyl Chemical group 0.000 claims description 4
- ZJIFDEVVTPEXDL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) hydrogen carbonate Chemical compound OC(=O)ON1C(=O)CCC1=O ZJIFDEVVTPEXDL-UHFFFAOYSA-N 0.000 claims description 2
- AASBXERNXVFUEJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) propanoate Chemical compound CCC(=O)ON1C(=O)CCC1=O AASBXERNXVFUEJ-UHFFFAOYSA-N 0.000 claims description 2
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical group CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 claims description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical group CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 claims description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical group C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 claims 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 8
- 208000010706 fatty liver disease Diseases 0.000 claims 7
- 108010011459 Exenatide Proteins 0.000 claims 5
- 125000003277 amino group Chemical group 0.000 claims 5
- 229960001519 exenatide Drugs 0.000 claims 5
- 102000004877 Insulin Human genes 0.000 claims 4
- 108090001061 Insulin Proteins 0.000 claims 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229940125396 insulin Drugs 0.000 claims 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 4
- 230000003248 secreting effect Effects 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 3
- 230000002473 insulinotropic effect Effects 0.000 claims 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 102100021538 Protein kinase C zeta type Human genes 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 235000003642 hunger Nutrition 0.000 claims 2
- 230000004130 lipolysis Effects 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 108010050991 protein kinase C zeta Proteins 0.000 claims 2
- 230000037351 starvation Effects 0.000 claims 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- 229920002101 Chitin Polymers 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 claims 1
- 108010027279 Facilitative Glucose Transport Proteins Proteins 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 208000002720 Malnutrition Diseases 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 101150116689 Slc2a2 gene Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 229920002988 biodegradable polymer Polymers 0.000 claims 1
- 239000004621 biodegradable polymer Substances 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000001071 malnutrition Effects 0.000 claims 1
- 235000000824 malnutrition Nutrition 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 1
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 150000001299 aldehydes Chemical group 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120024632A KR101665009B1 (ko) | 2012-03-09 | 2012-03-09 | 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물 |
| KR10-2012-0024632 | 2012-03-09 | ||
| PCT/KR2013/001897 WO2013133667A1 (en) | 2012-03-09 | 2013-03-08 | Pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017173062A Division JP2018009022A (ja) | 2012-03-09 | 2017-09-08 | 非アルコール性脂肪肝疾患の予防または治療のための医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015510880A JP2015510880A (ja) | 2015-04-13 |
| JP2015510880A5 true JP2015510880A5 (enExample) | 2017-06-01 |
Family
ID=49117073
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014560859A Pending JP2015510880A (ja) | 2012-03-09 | 2013-03-08 | 非アルコール性脂肪肝疾患の予防または治療のための医薬組成物 |
| JP2017173062A Pending JP2018009022A (ja) | 2012-03-09 | 2017-09-08 | 非アルコール性脂肪肝疾患の予防または治療のための医薬組成物 |
| JP2019177304A Pending JP2019214627A (ja) | 2012-03-09 | 2019-09-27 | 非アルコール性脂肪肝疾患の予防または治療のための医薬組成物 |
| JP2021178501A Pending JP2022025114A (ja) | 2012-03-09 | 2021-11-01 | 非アルコール性脂肪肝疾患の予防または治療のための医薬組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017173062A Pending JP2018009022A (ja) | 2012-03-09 | 2017-09-08 | 非アルコール性脂肪肝疾患の予防または治療のための医薬組成物 |
| JP2019177304A Pending JP2019214627A (ja) | 2012-03-09 | 2019-09-27 | 非アルコール性脂肪肝疾患の予防または治療のための医薬組成物 |
| JP2021178501A Pending JP2022025114A (ja) | 2012-03-09 | 2021-11-01 | 非アルコール性脂肪肝疾患の予防または治療のための医薬組成物 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20150056223A1 (enExample) |
| EP (1) | EP2838549B1 (enExample) |
| JP (4) | JP2015510880A (enExample) |
| KR (1) | KR101665009B1 (enExample) |
| CN (2) | CN110075277A (enExample) |
| AR (1) | AR090287A1 (enExample) |
| AU (1) | AU2013228152C1 (enExample) |
| CA (1) | CA2864250C (enExample) |
| DK (1) | DK2838549T3 (enExample) |
| ES (1) | ES2900823T3 (enExample) |
| HK (1) | HK1199220A1 (enExample) |
| HU (1) | HUE057245T2 (enExample) |
| IL (1) | IL234133B (enExample) |
| IN (1) | IN2014DN06694A (enExample) |
| MX (2) | MX2014010542A (enExample) |
| MY (1) | MY167214A (enExample) |
| NZ (1) | NZ628828A (enExample) |
| PH (1) | PH12014501785B1 (enExample) |
| PL (1) | PL2838549T3 (enExample) |
| PT (1) | PT2838549T (enExample) |
| RU (1) | RU2635966C2 (enExample) |
| SG (1) | SG11201404733UA (enExample) |
| TW (2) | TWI658835B (enExample) |
| WO (1) | WO2013133667A1 (enExample) |
| ZA (1) | ZA201405918B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2721062T1 (sl) | 2011-06-17 | 2019-03-29 | Hanmi Science Co., Ltd. | Konjugat, obsegajoč oksintomodulinski in imunoglobinski fragment, in uporaba le-tega |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| US9724420B2 (en) | 2012-11-06 | 2017-08-08 | Hanmi Pharm. Co., Ltd. | Liquid formulation of protein conjugate comprising an oxyntomodulin derivative covalently linked to a non-peptidyl polymer to an immunoglobulin FC region |
| MX369656B (es) | 2014-01-20 | 2019-11-15 | Hanmi Pharm Ind Co Ltd | Insulina de accion prolongada y uso de la misma. |
| AR100639A1 (es) * | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
| TWI684458B (zh) | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物 |
| TWI802396B (zh) * | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| CR20180034A (es) * | 2015-06-30 | 2018-04-16 | Hanmi Pharm Ind Co Ltd | Derivados de glucagón y una composición que comprende un conjugado de acción prolongada del mismo. |
| UY36870A (es) | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
| EP4534107A3 (en) * | 2015-09-24 | 2025-12-10 | Hanmi Pharm. Co., Ltd. | Protein complex by use of a specific site of an immunoglobulin fragment for linkage |
| EP3384935A4 (en) * | 2015-12-02 | 2019-08-21 | Hanmi Pharm. Co., Ltd. | PROTEIN COMPLEX WITH FATTY ACID DERIVATIVE AND MANUFACTURING METHOD THEREFOR |
| AU2017332408B2 (en) | 2016-09-23 | 2022-02-10 | Hanmi Pharm. Co., Ltd. | Insulin analogs with reduced affinity to insulin receptor and use thereof |
| KR101906333B1 (ko) | 2016-12-07 | 2018-10-11 | 고려대학교 산학협력단 | 지방간의 진단 또는 치료를 위한 류신 지퍼 단백질의 용도 |
| KR101964743B1 (ko) | 2017-01-19 | 2019-08-14 | 울산대학교 산학협력단 | Gnpat을 유효성분으로 포함하는 비알콜성 지방간염 진단용 또는 치료 예후 예측용 바이오마커 조성물 |
| AU2018239037B2 (en) | 2017-03-23 | 2022-05-26 | Hanmi Pharm. Co., Ltd. | Insulin analog complex with reduced affinity for insulin receptor and use thereof |
| CN109248323B (zh) * | 2017-07-14 | 2023-09-08 | 杭州先为达生物科技有限公司 | 酰化的glp-1衍生物 |
| EP3437651A1 (en) * | 2017-08-03 | 2019-02-06 | Université de Strasbourg | Peptides for treatment and prevention of nonalcoholic fatty liver disease |
| KR102174436B1 (ko) * | 2017-08-17 | 2020-11-04 | 주식회사 엘지화학 | 불용성 안료 화합물의 정성분석방법 |
| KR20200135618A (ko) | 2019-05-23 | 2020-12-03 | ㈜ 디앤디파마텍 | 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물 |
| EP3823659A4 (en) * | 2018-07-19 | 2022-06-22 | D&D Pharmatech Inc. | PHARMACEUTICAL COMPOSITION WITH A POLYPEPTIDE |
| KR102177304B1 (ko) * | 2018-07-23 | 2020-11-10 | 제이투에이치바이오텍 (주) | 비알콜성 지방간염의 예방 또는 치료용 약학 조성물 |
| CN110151980B (zh) * | 2019-06-30 | 2022-12-09 | 中国药科大学 | Glp-1受体激动剂融合蛋白在制备预防或治疗高血脂药物中的应用 |
| KR102315866B1 (ko) * | 2020-03-24 | 2021-10-21 | 한국원자력의학원 | 섬유화 질환 복합 치료제 개발 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
| US5424686A (en) | 1994-04-20 | 1995-06-13 | Philips Electronics North America Corporation | Negative-resistance-compensated microwave buffer |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| KR101135244B1 (ko) * | 2007-11-29 | 2012-04-24 | 한미사이언스 주식회사 | 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물 |
| US8263084B2 (en) * | 2003-11-13 | 2012-09-11 | Hanmi Science Co., Ltd | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
| CA2545023A1 (en) * | 2003-11-25 | 2005-06-09 | Novo Nordisk A/S | Novel salicylic anilides |
| WO2007022518A2 (en) * | 2005-08-19 | 2007-02-22 | Amylin Pharmaceuticals, Inc. | New uses of glucoregulatory proteins |
| JP2008169195A (ja) * | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| US20100033010A1 (en) * | 2007-03-06 | 2010-02-11 | Bridgestone Corporation | Rubber track |
| US8249718B2 (en) * | 2008-07-11 | 2012-08-21 | Medtronic, Inc. | Programming posture state-responsive therapy with nominal therapy parameters |
| KR101200659B1 (ko) | 2008-07-23 | 2012-11-12 | 한미사이언스 주식회사 | 세 말단 반응기를 갖는 비펩타이드성 중합체를 이용한 생리활성 폴리펩타이드 약물 결합체 |
| EP2248449A1 (en) * | 2009-05-08 | 2010-11-10 | Koninklijke Philips Electronics N.V. | Kitchen appliance |
| WO2011109787A1 (en) * | 2010-03-05 | 2011-09-09 | Conjuchem, Llc | Methods of administering insulinotropic peptides |
| KR101382593B1 (ko) * | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
-
2012
- 2012-03-09 KR KR1020120024632A patent/KR101665009B1/ko active Active
-
2013
- 2013-03-08 SG SG11201404733UA patent/SG11201404733UA/en unknown
- 2013-03-08 HU HUE13757286A patent/HUE057245T2/hu unknown
- 2013-03-08 MY MYPI2014002334A patent/MY167214A/en unknown
- 2013-03-08 CN CN201811396462.4A patent/CN110075277A/zh active Pending
- 2013-03-08 JP JP2014560859A patent/JP2015510880A/ja active Pending
- 2013-03-08 TW TW102108194A patent/TWI658835B/zh active
- 2013-03-08 ES ES13757286T patent/ES2900823T3/es active Active
- 2013-03-08 EP EP13757286.3A patent/EP2838549B1/en active Active
- 2013-03-08 NZ NZ628828A patent/NZ628828A/en unknown
- 2013-03-08 PT PT137572863T patent/PT2838549T/pt unknown
- 2013-03-08 PL PL13757286T patent/PL2838549T3/pl unknown
- 2013-03-08 CN CN201380013141.0A patent/CN104159597A/zh active Pending
- 2013-03-08 DK DK13757286.3T patent/DK2838549T3/da active
- 2013-03-08 RU RU2014133615A patent/RU2635966C2/ru active
- 2013-03-08 CA CA2864250A patent/CA2864250C/en active Active
- 2013-03-08 AU AU2013228152A patent/AU2013228152C1/en active Active
- 2013-03-08 US US14/383,954 patent/US20150056223A1/en not_active Abandoned
- 2013-03-08 IN IN6694DEN2014 patent/IN2014DN06694A/en unknown
- 2013-03-08 WO PCT/KR2013/001897 patent/WO2013133667A1/en not_active Ceased
- 2013-03-08 AR ARP130100760A patent/AR090287A1/es unknown
- 2013-03-08 MX MX2014010542A patent/MX2014010542A/es unknown
- 2013-03-08 HK HK14112891.9A patent/HK1199220A1/xx unknown
- 2013-03-08 TW TW107146976A patent/TW201919688A/zh unknown
-
2014
- 2014-08-07 PH PH12014501785A patent/PH12014501785B1/en unknown
- 2014-08-13 ZA ZA2014/05918A patent/ZA201405918B/en unknown
- 2014-08-14 IL IL234133A patent/IL234133B/en active IP Right Grant
- 2014-09-03 MX MX2020001697A patent/MX2020001697A/es unknown
-
2017
- 2017-09-08 JP JP2017173062A patent/JP2018009022A/ja active Pending
-
2019
- 2019-09-27 JP JP2019177304A patent/JP2019214627A/ja active Pending
-
2021
- 2021-11-01 JP JP2021178501A patent/JP2022025114A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015510880A5 (enExample) | ||
| JP2022025114A5 (enExample) | ||
| RU2014133615A (ru) | Фармацевтическая композиция для предупреждения или лечения неалкогольной жировой болезни печени | |
| KR102434280B1 (ko) | 옥신토모듈린과 면역글로불린 단편을 포함하는 단백질 결합체의 액상 제제 | |
| KR102762409B1 (ko) | 지속형 glp-1/글루카곤 수용체 듀얼 아고니스트의 비알콜성 지방간질환에 대한 용도 | |
| JP2015503554A5 (enExample) | ||
| JP6903086B2 (ja) | オキシントモジュリン誘導体を含む高脂血症の治療のための組成物 | |
| JP2017529354A5 (enExample) | ||
| NZ585314A (en) | A pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate | |
| KR20220042326A (ko) | 면역글로불린 Fc 단편 결합을 이용한 단백질 및 펩타이드의 용해도를 개선시키는 방법 | |
| RU2015138536A (ru) | Новый аналог инсулина и его применение | |
| JP2015536943A5 (enExample) | ||
| WO2009075859A3 (en) | Formulation of insulinotropic peptide conjugates | |
| RU2012146663A (ru) | Конъюгат инсулина с применением фрагмента иммуноглобулина | |
| JP2019524675A5 (enExample) | ||
| CA2890329A1 (en) | A composition for treating diabetes or diabesity comprising oxyntomodulin analog | |
| WO2008000516A3 (en) | IMPROVED sgp130Fc DIMERS | |
| JP2013533875A5 (enExample) | ||
| NZ764889B2 (en) | Composition for treating diabetes mellitus comprising insulin and a GLP-1/glucagon dual agonist | |
| NZ727871B2 (en) | Composition for treating diabetes mellitus comprising insulin and a glp-1/glucagon dual agonist | |
| NZ750267A (en) | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof | |
| NZ750267B2 (en) | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof | |
| NZ724926B2 (en) | Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage | |
| HK1147958A (en) | Formulation of insulinotropic peptide conjugates |